Danaher: 3 Key Takeaways for Long-Term Investors
Portfolio reshaping complete, management now pivots to organic growth and disciplined acquisitions to compound returns.
Danaher reported stronger third-quarter 2026 earnings growth, signaling rising demand in bioprocessing and clinical diagnostic markets. CEO Julie Sawyer Montgomery noted that the company has completed major portfolio reshaping, now focusing on effectively selling its products to achieve market share growth. Biotechnology customers are expanding production, driving mid-single-digit sales growth and double-digit order acceleration, particularly for upstream consumables and reagents.
Danaher plans to continue using mergers and acquisitions to enhance its portfolio, while adhering to its strict investment criteria. The company expects core revenue growth between 4% and 5% in 2027, with strong performance across all operating segments as end markets recover. Management remains committed to AI integration in lab workflows and commercial execution.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
